EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Thymol as adjuvant in oncology: molecular mechanisms, therapeutic potentials, and prospects for integration in cancer management

Jesús Herrera-Bravo, Lisandra Herrera Belén, María Elena Reyes, Victor Silva, Soledad Fuentealba, Cristian Paz, Pía Loren, Luis A Salazar, Javad Sharifi-Rad, Daniela Calina

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024-11 · 397 (11) · 8259-8284

DOI: 10.1007/s00210-024-03196-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 07.06.2024. Verfasst von Jesús Herrera-Bravo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Santiago, Chile. Hauptthemen laut MEDLINE: Thymol, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 162 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a global health challenge, prompting a search for effective treatments with fewer side effects. Thymol, a natural monoterpenoid phenol derived primarily from thyme (Thymus vulgaris) and other plants in the Lamiaceae family, is known for its diverse biological activities. It emerges as a promising candidate in cancer prevention and therapy. This study aims to consolidate current research on thymol's anticancer effects, elucidating its mechanisms and potential to enhance standard chemotherapy, and to identify gaps for future research. A comprehensive review was conducted using databases like PubMed/MedLine, Google Scholar, and ScienceDirect, focusing on studies from the last 6 years. All cancer types were included, assessing thymol's impact in both cell-based (in vitro) and animal (in vivo) studies. Thymol has been shown to induce programmed cell death (apoptosis), halt the cell division cycle (cell cycle arrest), and inhibit cancer spread (metastasis) through modulation of critical signaling pathways, including phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), extracellular signal-regulated kinase (ERK), mechanistic target of rapamycin (mTOR), and Wnt/β-catenin. It also enhances the efficacy of 5-fluorouracil (5-FU) in colorectal cancer treatments. Thymol's broad-spectrum anticancer activities and non-toxic profile to normal cells underscore its potential as an adjunct in cancer therapy. Further clinical trials are essential to fully understand its therapeutic benefits and integration into existing treatment protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThymolNeoplasmsHumansAnimalsAntineoplastic AgentsApoptosisAntineoplastic Agents, PhytogenicSignal TransductionChemotherapy, Adjuvant

Stichwörter der Autor:innen

Anticancer mechanismsApoptosisChemotherapeutic synergismChemotherapy enhancementNatural compounds thymol

Substanzen

ThymolAntineoplastic AgentsAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Santiago, Chile.
  • Instituto de Ciencias Biomédicas, Facultad de Ciencias de La Salud, Universidad Autónoma de Chile, Temuco, Chile.
  • Laboratorio de Investigación en Salud de Precisión, Departamento de Procesos Diagnósticos y Evaluación, Facultad de Ciencias de La Salud, Universidad Católica de Temuco, Temuco, Chile.
  • Laboratory of Natural Products & Drug Discovery, Department of Basic Sciences, Faculty of Medicine, Center CEBIM, Universidad de La Frontera, Temuco, Chile.
  • Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, 4811230, Temuco, Chile.
  • Department of Biomedical Sciences, College of Medicine, Korea University, Seoul, Republic of Korea. javad.sharifirad@gmail.com.

Zitieren

APA

Herrera-Bravo, J., Belén, L. H., Reyes, M. E., Silva, V., Fuentealba, S., Paz, C., Loren, P., Salazar, L. A., Sharifi-Rad, J., & Calina, D. (2024). Thymol as adjuvant in oncology: molecular mechanisms, therapeutic potentials, and prospects for integration in cancer management. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(11), 8259-8284. https://doi.org/10.1007/s00210-024-03196-3

Vancouver

Herrera-Bravo J, Belén LH, Reyes ME, Silva V, Fuentealba S, Paz C, et al. Thymol as adjuvant in oncology: molecular mechanisms, therapeutic potentials, and prospects for integration in cancer management. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(11):8259-8284. doi:10.1007/s00210-024-03196-3

BibTeX
@article{HerreraBravo2024,
  author = {Herrera-Bravo, Jesús and Belén, Lisandra Herrera and Reyes, María Elena and Silva, Victor and Fuentealba, Soledad and Paz, Cristian and Loren, Pía and Salazar, Luis A and Sharifi-Rad, Javad and Calina, Daniela},
  title = {Thymol as adjuvant in oncology: molecular mechanisms, therapeutic potentials, and prospects for integration in cancer management},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  volume = {397},
  number = {11},
  pages = {8259--8284},
  doi = {10.1007/s00210-024-03196-3}
}
Kostenlos starten →